Novartis announces option exercise and merger proposal

Article

Novartis is to exercise its option to purchase the remaining shares in Alcon, Inc., owned by Nestle S.A. at a weighted average price of US$180 per share in cash following the agreement between Nestle and Novartis in April 2008.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
An image of Salt Lake City, Utah, with the skyline visible between a mountain range in the background and a passing train in the foreground. Concept image for ARVO Association for Research in Vision and Ophthalmology. Image credit: ©f11photo – stock.adobe.com

Industry updates and clinical trial data at the upcoming 2025 ARVO Annual Meeting

Sydney M Crago
April 18th 2025
Article

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Two hands reach towards a logo which says "AI," for artificial intelligence. Concept image for AI screenings for neovascular age-related macular degeneration. Image credit: ©deagreez – stock.adobe.com

Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab

Lynda Charters
April 17th 2025
Article

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

A phone with several social media apps on the screen. Concept image for social media usage in clinical follow-up. Image credit: ©Tada Images – stock.adobe.com

Clinicians may improve follow-up adherence by leveraging social media apps

Lynda Charters
April 16th 2025
Article

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

An image which shows a translucent head, with the eye, brain and optic nerve highlighted. Concept for brain-eye neurology neuroinflammation connection. Image credit: ©jitendra jadhav – stock.adobe.com

Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104

Sydney M Crago
April 16th 2025
Article

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Signage labaelling the Alcon Grieshaber AG facility in Schaffhausen, Switzerland. Image courtesy of Alcon.

Alcon marks 110th anniversary of Grieshaber AG site in Switzerland

Hattie Hayes
April 15th 2025
Article

Alcon acquired the historic ophthalmic instrument company in 2000

© 2025 MJH Life Sciences

All rights reserved.